Hasil Pencarian - Jon Ukropec

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    P1176: CLINICAL OUTCOMES OF NOVEL THERAPIES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

    P1176: CLINICAL OUTCOMES OF NOVEL THERAPIES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA oleh Jennifer Crombie, Monika Jun, Tongsheng Wang, Alex Mutebi, Anthony Wang, Anindit Chibber, Rajesh Kamalakar, Jon Ukropec, Julie Blaedel, Anupama Kalsekar

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

    Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma oleh Rafael Fonseca, Saad Z. Usmani, Maneesha Mehra, Mary Slavcev, Jianming He, Sarah Cote, Annette Lam, Jon Ukropec, Eric M. Maiese, Sandhya Nair, Ravi Potluri, Peter M. Voorhees

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

    Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and... oleh Maria-Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Ludek Pour, Katja Weisel, Michele Cavo, Jacob P. Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Z. Usmani, Sung-Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jon Ukropec, Jordan M. Schecter, Xiang Qin, Lisa O’Rourke, Meletios A. Dimopoulos

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

    Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk oleh Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: